Emergent BioSciences closes sale of Baltimore-Camden facility to Bora for $30M

Emergent BioSolutions Inc.

Sold drug product facility in Baltimore-Camden to affiliate of Bora Pharmaceuticals (TWSE:6472) for ~$30M at closing.
Bora acquired all assets, equipment, and workforce associated with the 87,000 sq ft facility.
CEO Joe Papa says sale is a step in multi-year plan to stabilize, improve profitability, and reduce debt.
Truist Securities and Covington & Burling advised Emergent on the transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.